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Summary: The hydroxyproline/creatinine ratio for two groups of healthy individuals and two groups of patients with
a history of mammary and prostatic carcinoma without metastases was measured and compared with literature values.
The hydroxyproline/creatinine ratio for healthy adults appears to be 1.4 (range 0.7-2.3). Furthermore, the influence
of diet and gelatin load of 30 g on the hydroxyproline creatinine ratio and the hydroxyproline excretion has been
investigated. The analytical characteristics of the test used in the present study were evaluated using the method of
standard additions. An intra-assay quality-control on the basis of the standard addition is proposed. The coefficient
of variation of the hydroxypyroline/creatinine ratio appears to be 22%. The intraindividual variability has also been
established for the hydroxyproline/creatinine ratio and appears to be 25%.
Referenzwerte und analytische Ermittlung des Hydroxyprolin/Kreatinin-Quotienten in Proben von Morgenurin
Zusammenfassung: Der Hydroxyprolin/KreatinüvQuotient wurde bei zwei Gruppen Gesunder und zwei Gruppen
mit der Anamnese von Mamma- bzw. Prostata-Carcinom ohne Metastasen bestimmt und mit Werten der Literatur
verglichen. Der Hydroxyprolin/Kreatinin-Quotient für gesunde Erwachsene ergab sich zu 1,4 (Bereich 0,7-2,3).
Weiterhin wurde der Einfluß der Nahrung und einer Belastung mit 30 g Gelatine auf den Hydroxyprolin/Kreatinin-
Quotienten und die Hydroxyprolinausscheidung untersucht. Die analytischen Charakteristika für den hier verwen-
deten Test wurden mit der Methode der Standardaddition geprüft. Auf der Grundlage der Standardaddition wird
eine Qualitätskontrolle in jeder Probe vorgeschlagen. Der Variationskoeffizient für den Hydroxyprolin/Kreatinin-
Quotienten ergab sich zu 22%, die intraindividuelle Variabilität zu 25%.
Introduction
Hydroxyproline excretion in urine has been reported to
be useful for monitoring patients with mammary carci-
noma or prostatic carcinoma, for the detection of bone
metastases (1-^7).
Also, it is particularly useful in the clinical follow up,
for the evaluation of the response to treatment.
However, until recently hydroxyproline excretion was
measured in accurately collected 24-hour urine samples.
Since the hydroxyproline excretion may be influenced
by dietary collagen, a collagen-free diet before and
during the urine collection is considered necessary.
It will be clear that the collection of the 24-hour urine
during a collagen free diet is rather troublesome for
routine use in an outpatients clinic. A simplification of
the procedure has been proposed byPowles et al. (8)
using an early morning urine sample collected after a 10-
hour overnight fast. Recently a comparison was made
between eaxly morning urine hydroxyproline levels and
hydroxyproline excretion (9, 10). The present investi-
gation is part of a clinical study of patients with
mammary carcinoma and prostatic carcinoma during
a two-year follow up with emphasis on the detection of
bone metastasis. Since reported reference values for the
hydroxyproline/creatinine ratio in early morning urine
(3—6, 8, 9) showed large differences, the authors found
it necessary to evaluate the hydroxyproline creatine/
ratio for normal healthy individuals and for patients
without metastases. Furthermore, since the coefficient
of variation of the hydroxyproline/creatinine ratio was
relatively large it appeared indispensable for the inter-
pretation of the results to investigate the intraindividual
variability of the hydroxyproline/creatinine ratio.
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Materials and Methods
Volunteers
25 normal healthy laboratory workers (18 females, 7 males,
age 21-42 years) participated in the investigation.
They followed the following protocol for 5 days:
ist day: starting at 8.00 hours with collagen-free diet.
2nd day: collagen-free diet continued; 24-hour urine collection
started after the first morning quantity had been
voided.
3rd day: first morning urine collected and kept separate from
the 24-hour urine. A small portion of this first morning
urine was used for analyses and the remaining portion
was added to the 24-hour urine. Diet then discon-
tinued. At 22.00 hours overnight fast started
(no food or drinks).
4th day: first quantity of urine discarded. Fasting then con-
tinued and a urine sample collected after about
30-60 min. At about 15.00 hours 30 g gelatin dis-
solved in fruit juice was taken per os. At 22.00 hours
overnight fast started.
5th day: first morning urine discarded. Urine sample then
collected after about 30-60 min.
Another 58 healthy adults (44 females and 14 males, age 21—63
years) cooperated to collect a spot early morning urine after an
overnight fast (no food, no drinks) starting at 22.00 hours. The
first morning urine had to be discarded and a following urine
sample was collected after about 30-60 min.
Patients
26 patients with biopsy-proven mammary carcinoma without any
metastases (age: mean 62 years, range 39-83 years); and 24
patients with biopsy-proven prostatic carcinoma without any
metastases (age: mean 74 years, range 60-90 years), collected,
every 3 to 4 months, a spot fasting morning urine during their
visit to the laboratory.
Before this investigation all patients with mammary carcinoma
and prostatic carcinoma were operated and underwent a thorough
clinical evaluation for full staging and assessment on the basis
of careful examination by a surgeon or an urologist.
Extensive laboratory and radiological investigations were per-
formed including: bone scan (Tc polyphosphate); chest X-ray
and skeletal survey; routine haematology; renal function; liver
function; C.E.A.; á-feto protein; ferritin; biopsy for histological
examinations.
During this investigation the patients had normal renal function,
and there were no indications of other metabolic diseases.
Procedure
Hydroxyproline in urine was measured by means of the hypro-
nosticon test kit (Organon n.v., Oss, The Netherlands). The test
involves hydrolysis of peptide bound hydroxyproline.
The hydroxyproline is oxidized to pyrrole compounds that
form a specific colour reaction with p-dimethylaminobenz-
aldehyde. The absorbance of the coloured compound is measured
at 520 nm. A detailed description of test principles and reagents
has been outlined by Goverde & Veenkamp (11) and by others
(12).
The Urines were analyzed in duplicate: two urine tubes Ul and
U2; two urine + standard tubes SI and S2; and two blank tubes
Bl and B2. Standardization was performed by means of standard
addition to each sample. The amount added was 382 ìçéïÀ.
Creatinirie measurements were performed by means of a standard
Technicon Autoanalyzer method.
Urine samples: all urines were frozen and kept at — 20 °C prior
to determination.
Results and Discussion
Since each hydroxyproline measurement is standardized
by means of standard addition, this means that quality
control can be performed on each individual sample.
The possibility of individual sample quality control
follows from measurement of the increase in absorbance
caused by the addition of standard. On the basis of
linearity of the working curve this increase in absorbance
should be constant, depending only on the variability
of the absorbance readings.
The variability of the absorbance readings was studied
within a series and during 15 series.
On the basis of these results it was obvious that the co-
efficient of variation of the hydroxyproline creatinine
ratio appeared to be 22%.
Furthermore» it was clear that every result with an in-
crease in absorbance outside the range 0.400—0.585
had to be omitted. The urines of the 25 volunteers
who undertook the five-day protocol were analysed.
The results of the hydroxyproline excretion and hydroxy-
prolirie/creatinine ratios are summarized in table 1.
Furthermore, the results of another collection of fasting
morning urines of 58 volunteers (different from the first
group), who recently served s reference group for our
laboratory, have been included in table 1.
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! An outlier of 29 mmol/mol has been deleted.
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Evidently, the hydroxyproline creatinine ratio is not
influenced by normal dietary intake of collagen, since
there are no significant differences between early
morning urine with and without diet. Also the hydroxy-
proline/creatinine ratio of the reference group is not
significantly different from the values for the first group
of volunteers. Between both measurements there was a
time lag of one year, indicating that the method appears
to be reproducible over long periods using different
batch numbers of reagents.
The normal values for the hydroxyproline excretion as
shown in table 1, are slightly lower than the reference
values as stated by the kit supplier.
As is clearly demonstrated from the figures of table 1,
the hydroxyproline/creatinine ratios increase significantly
after a dietary load of 30 g gelatin. Since normal dietary
hydroxyproline intake is relatively low it will be clear
that the risk of false high values due to excessive
dietary intake is low compared to other risks of false
positive results e.g. intra individual variations. Also from
table 1 it will be obvious that the influence of dietary
intake on fasting hydroxyproline excretion is not
measurable.
Comparison of reference values with the hydroxy-
proline/creatinine ratios from the literature was con-
fusing: Firstly, because the literature values are often
expressed as g/g ratio. Secondly, a great number of
literature results were deduced from patient groups
with benign tumours or patients (mammary carcinoma,
prostatic carcinoma) without metastases.
The reference values found in the literature are given
in table 2. These values show a rather large variability,
possibly caused by method differences, and material
differences. The upper limits of the normal values range
from 2.3 to 4.3.
To study the possible differences between healthy in-
dividuals and patients without bone metastases, we
have included in this study a 1 year follow up of 26
patients with a history of mammary carcinoma and
24 patients with a history of prostatic carcinoma.
Furthermore it was important for the interpretation
of hydroxyproline/creatinine ratios to know the intra-
Tab. 3. Intra-individual variations in hydroxyproline/creatinine
ratio in early morning urine of 24 patients with prostatic
carcinoma without proven metastases.
The patients visited the outpatient clinic every 3 to 4



































































































































individual variability of results. The follow up results
of these groups of patients without metastases and
with normal renal function are presented in table 3
and 4. The mean hydroxyproline creatinine ratios of
1.2 and 1.3 are not significantly different from the
reference values discussed above. This means that our
group of patients gave the same results as the "normal"
groups, indicating that the above mentioned differences
in literature values have to be attributed to method dif-
ferences alone. The mean coefficients of variation of the
patient results during a year follow up, appeared to be 27%
and 24% for the group of mammary carcinoma patients
and prostatic carcinoma patients, respectively. Since the
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Tab. 4. Intra-individual variations in hydroxyproline/crea-
tinine ratio in early morning urine of 26 patients
with mammary carcinoma, without proven meta-
stases. The patients visited the outpatients clinic every
3 to 4 months, during a follow up after treatment,
at least 4 times.










































































































































method error is 22%, this implies that the individual
results are significantly influenced by the analytical
variability of the method.
However, due to these relatively large variations, we feel
that the hydroxyproline/creatinine ratio can be used in
follow up studies, but every borderline result should be
repeated. In conclusion it can be said that the reference
values for a group of normal adults is not significantly
different from a group of patients with a history of
mammary carcinoma or prostatic carcinoma and with-
out proven metastases.
Furthermore, it is very important, at least with the
used technique, to perform standard addition on every
sample for quality control.
Since the intraindividual variability can be consider-
able, it is advisable to use a series of results per patient
in the interpretation.
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